P Pautier

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy
    P Morice
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Eur J Gynaecol Oncol 25:169-74. 2004
  2. doi request reprint Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
    Patricia Pautier
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Oncol 116:157-62. 2010
  3. doi request reprint A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, Cedex, France
    Ann Oncol 24:1099-104. 2013
  4. pmc Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
    Patricia Pautier
    Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, France
    Oncologist 17:1213-20. 2012
  5. ncbi request reprint [Cancer and pregnancy: the point of view of the chemotherapy oncologist]
    Patricia Pautier
    Comité de gynécologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 89:779-85. 2002
  6. ncbi request reprint [Gemicitabine in the treatment of epithelial ovarian cancer]
    Patricia Pautier
    Service de gynécologie médicale, Département de médecine adulte, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 89:S115-9. 2002
  7. ncbi request reprint [Cancer and pregnancy: the medical oncologist's point of view]
    P Pautier
    Service de Gynecologie, Institut Gustave Roussy, Villejuif
    J Gynecol Obstet Biol Reprod (Paris) 33:S23-8. 2004
  8. ncbi request reprint Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors
    P Pautier
    Departments of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 18:446-52. 2008
  9. ncbi request reprint Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 12:749-54. 2002
  10. ncbi request reprint Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
    P Pautier
    Medical Department, Gynecological Unit, Institut Gustave Roussy, 94805 Villejuif, France
    Hum Reprod 16:2434-7. 2001

Detail Information

Publications97

  1. ncbi request reprint Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy
    P Morice
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Eur J Gynaecol Oncol 25:169-74. 2004
    ..To report the rates of nodal involvement in epithelial ovarian cancer (EOC) in patients who underwent initial lymphadenectomy (before chemotherapy) and patients who underwent lymphadenectomy after chemotherapy...
  2. doi request reprint Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
    Patricia Pautier
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Oncol 116:157-62. 2010
    ..This phase II investigated efficacy and tolerability of gefitinib in combination with paclitaxel (P) and carboplatin (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal adenocarcinoma...
  3. doi request reprint A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, Cedex, France
    Ann Oncol 24:1099-104. 2013
    ..SARCGYN phase III study compared adjuvant polychemotherapy followed by pelvic radiotherapy (RT) (arm A) versus RT alone (arm B) conducted to detect an increase ≥ 20% of 3-year PFS...
  4. pmc Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
    Patricia Pautier
    Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, France
    Oncologist 17:1213-20. 2012
    ..This study aimed to evaluate the efficacy and toxicity of single-agent gemcitabine versus gemcitabine plus docetaxel as second-line therapy in patients with uterine and nonuterine leiomyosarcoma (LMS)...
  5. ncbi request reprint [Cancer and pregnancy: the point of view of the chemotherapy oncologist]
    Patricia Pautier
    Comité de gynécologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 89:779-85. 2002
    ..Regarding the long term risks of cancer on fertility or child's intellectual development, they are still not well known and must be included into prospective studies, as well as being registered in a specific data file...
  6. ncbi request reprint [Gemicitabine in the treatment of epithelial ovarian cancer]
    Patricia Pautier
    Service de gynécologie médicale, Département de médecine adulte, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 89:S115-9. 2002
    ..The response rates that have been obtained appear to be very encouraging (between 61% and 67%) and fully justify the recent phase III trials conducted in first line...
  7. ncbi request reprint [Cancer and pregnancy: the medical oncologist's point of view]
    P Pautier
    Service de Gynecologie, Institut Gustave Roussy, Villejuif
    J Gynecol Obstet Biol Reprod (Paris) 33:S23-8. 2004
    ..The long-term risks of cancer on the mother's subsequent fertility or the child's intellectual development are not well-known. Such factors must be examined in prospective studies and registered in a specific database...
  8. ncbi request reprint Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors
    P Pautier
    Departments of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 18:446-52. 2008
    ..Five patients experienced a low bleomycin pulmonary toxicity. BEP regimen appears to be an active regimen for OGCT in first-line chemotherapy...
  9. ncbi request reprint Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 12:749-54. 2002
    ..Median overall survival was 14 month overall, 45 months for Group 1 and 13 months for Group 2. We conclude that the DECAV regimen is clearly active in uterine sarcomas but is too toxic to be recommended routinely...
  10. ncbi request reprint Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
    P Pautier
    Medical Department, Gynecological Unit, Institut Gustave Roussy, 94805 Villejuif, France
    Hum Reprod 16:2434-7. 2001
    ..The study was conducted to evaluate whether the detection of serum molecular forms of inhibin (A and B) could be useful for the diagnosis, prognosis and follow-up of placental tumours...
  11. ncbi request reprint Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
    Int J Gynecol Cancer 14:1112-7. 2004
    ..Compared to a case-control study of adjuvant radiotherapy alone, results were not decreased by the addition of a toxic chemotherapy...
  12. ncbi request reprint Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:1985-9. 2007
    ..The evaluation of first-line intensive combination therapy in small cell carcinoma of the ovary (SCCO)...
  13. ncbi request reprint Prognosis of stage III or IV primary peritoneal serous papillary carcinoma
    G Dubernard
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Surg Oncol 30:976-81. 2004
    ..To study the prognosis of patients with stage IIIC/IV primary peritoneal serous papillary carcinoma (PSPC) (study group) compared with that of patients with epithelial ovarian carcinoma (EOC) (control group)...
  14. ncbi request reprint Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients
    P Morice
    Department of Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France
    Eur J Gynaecol Oncol 24:237-40. 2003
    ..The aim of this series was to study the clinical impact of initial surgical management, particularly of uterine morcellation. on patients treated for uterine sarcoma (US)...
  15. doi request reprint [First line chemotherapy of advanced epithelial ovarian cancer]
    C Lhomme
    Institut Gustave Roussy, Comité de gynécologie, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 96:1207-13. 2009
    ..As for numerous cancerous pathologies, the targeted therapies, notably the antiangiogenic one, represent an important hope in the treatment of the ovarian cancer...
  16. ncbi request reprint [Surgery for uterine sarcoma: review of the literature and recommendations for the standard surgical procedure]
    P Morice
    Service de chirurgie oncologique gynécologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805, Villejuif, France
    Gynecol Obstet Fertil 31:147-50. 2003
    ..Surgical resection should be ideally performed without uterine parcelling out and so using a laparotomy in order to avoid this risk...
  17. doi request reprint Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor
    T de La Motte Rouge
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif
    Ann Oncol 19:1435-41. 2008
    ..Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy. However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known...
  18. ncbi request reprint Results of conservative treatment in epithelial ovarian carcinoma
    P Morice
    Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Cancer 92:2412-8. 2001
    ..The objective of this study was to assess and evaluate the clinical outcome and fertility in patients treated conservatively for epithelial ovarian carcinoma (EOC)...
  19. ncbi request reprint Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study
    P Morice
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 14:74-7. 2003
    ..To study the results of interval debulking surgery (IDS) in patients treated for 'unresectable' advanced stage ovarian cancer compared with primary debulking surgery (PDS) followed by chemotherapy...
  20. doi request reprint [Postoperative morbidity after completion surgery following homogeneous chemoradiation therapy in locally advanced cervical cancer]
    C Touboul
    Département de chirurgie gynécologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    J Gynecol Obstet Biol Reprod (Paris) 39:624-31. 2010
    ..To evaluate the morbidity rate in patients following completion surgery (hysterectomy±lymphadenectomy) after chemoradiation therapy (CRT) for an advanced stage cervical cancer...
  21. ncbi request reprint [Prognostic factors and treatment for advanced-stage borderline ovarian tumors]
    P Morice
    Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Gynecol Obstet Biol Reprod (Paris) 31:623-8. 2002
    ..The aim of this review is to study the incidence, the prognostic factors and the treatment of patients with advanced stage borderline ovarian tumor (BOT) associated with extra-ovarian disease (peritoneal implants and/or nodal disorders)...
  22. doi request reprint Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma
    G G Malouf
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Ann Oncol 21:2102-6. 2010
    ..The historical options usually discussed in addition to hysterectomy and bilateral salpingoophorectomy (BSO) are active surveillance, pelvic radiotherapy, chemotherapy and hormonal therapy, alone or in combination...
  23. ncbi request reprint [Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy]
    F Joulie
    Département de chirurgie oncologique gynécologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Obstet Fertil 32:502-7. 2004
    ....
  24. ncbi request reprint Prognostic factors for patients with advanced stage serous borderline tumours of the ovary
    P Morice
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 14:592-8. 2003
    ..The aim of this study was to determine the prognostic factors for patients with advanced stage, low malignant potential ovarian tumour (LMPOT)...
  25. doi request reprint [Survival and prognostic factors after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer]
    C Touboul
    Département de chirurgie gynécologique, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Obstet Fertil 39:274-80. 2011
    ..The aim of this study was to evaluate the prognostic factors of patients undergoing completion surgery for locally advanced-stage cervical cancer after initial chemoradiation therapy (CRT)...
  26. ncbi request reprint Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis
    P Morice
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 14:1511-7. 2003
    ..Our aim was to study the prognostic value of the presence of lymphovascular space invasion (LVSI) in patients with stage IB and II cervical carcinoma treated by initial surgery...
  27. ncbi request reprint Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature
    S Delaloge
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Clin Oncol (R Coll Radiol) 12:357-62. 2000
    ..It may be that the introduction of chemotherapy, especially combined primary chemoradiotherapy, might allow patients to do a little better, although at the moment there is no good evidence one way or the other...
  28. ncbi request reprint [Results and fertility after conservative treatment of invasive epithelial ovarian cancer]
    P Morice
    Service de chirurgie oncologique gynécologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Obstet Fertil 30:684-91. 2002
    ..The aim of this study is to assess the clinical outcome and fertility in patients managed conservatively for epithelial ovarian cancer (EOC)...
  29. doi request reprint [Para-aortic lymphadenectomy in advanced-stage cervical cancer: standard procedure in 2010?]
    C Uzan
    Departement de Chirurgie, Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
    Gynecol Obstet Fertil 38:668-71. 2010
    ..Radiotherapy progress, especially with boost and combination to MRI (MRIT), will impact on future therapeutic management...
  30. ncbi request reprint Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy
    P Morice
    Department of Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:218-23. 2004
    ..The aim of this study was to determine the value of routine follow-up for the detection of recurrence in patients treated for cervical cancer...
  31. ncbi request reprint Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma
    S Faivre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:1479-89. 2002
    ....
  32. ncbi request reprint [Does adenocarcinoma of uterine cervix have a worse prognosis than squamous carcinoma?]
    A Recoules-Arche
    Service de chirurgie oncologique gynécologique, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Obstet Fertil 32:116-21. 2004
    ..The objective of this study was to examine the influence of histology on the outcome of patients with cervix carcinoma, treated with radiotherapy and radical surgery...
  33. ncbi request reprint [Laparoscopic treatment of borderline ovarian tumor: analysis of 54 patients and clinical outcomes]
    S Camatte
    Service de Chirurgie, Institut Gustave Roussy, Villejuif, France
    Gynecol Obstet Fertil 33:395-402. 2005
    ..The aim of this study is to assess the clinical outcomes of laparoscopic treatment of borderline ovarian tumor (BOT)...
  34. ncbi request reprint Clinical outcome after laparoscopic pure management of borderline ovarian tumors: results of a series of 34 patients
    S Camatte
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:605-9. 2004
    ..The aim of this study was to assess clinical outcome after laparoscopic treatment of borderline ovarian tumor (BOT)...
  35. ncbi request reprint [Modalities and limits of conservative treatment of adenocarcinoma in situ of the uterine cervix: analysis of nine cases and review of the literature]
    S Omnes
    Service de chirurgie oncologique gynécologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Obstet Fertil 31:912-9. 2003
    ..The aim of this study is to assess the results of conservative management of adenocarcinoma in situ (AIS) of the uterine cervix in young patients...
  36. ncbi request reprint Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol
    J P Lotz
    Department of Medical Oncology, Hopital Tenon, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    Bone Marrow Transplant 37:669-75. 2006
    ..Two episodes of grade IV diarrhoea were observed at level 9.5 mg/m2/day. Pharmacokinetic data were linear within the dose range of 4-9.0 mg/m2/day. The MTD was reached at 9 mg/m2/day x 5 days...
  37. ncbi request reprint Port-site metastasis after laparoscopic surgery for gynecologic cancer. A report of six cases
    P Morice
    Department of Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France
    J Reprod Med 45:837-40. 2000
    ..Port-site metastasis after laparoscopic surgery for gynecologic cancer is a recognized entity...
  38. doi request reprint Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern
    I Laurent
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    BJOG 116:860-2. 2009
    ..All women are currently disease free. Three women achieved a spontaneous pregnancy and three became pregnant after an in vitro fertilisation procedure. This study suggests that conservative treatment of SBOT-SMI is safe...
  39. ncbi request reprint Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer
    S Delaloge
    Department of Medical Oncology, H pital Paul Brousse, Villejuif, France
    Am J Clin Oncol 23:569-74. 2000
    ..This active combination shows acceptable hematologic toxicity, and reversible cumulative neurosensory toxicity. Further clinical exploration of the present combination appears warranted...
  40. ncbi request reprint Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer
    P Morice
    Department of Gynecologic Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Eur J Cancer 37:985-90. 2001
    ..Approximately two-thirds of this cost was due to systematic examinations (Pap smears and radiography). Our results indicate that such expenditure could be avoided...
  41. doi request reprint How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II-III serous borderline tumours of the ovary
    C Uzan
    Department of Gynecologic Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Ann Oncol 22:631-5. 2011
    ..The aim of this study was to describe how recurrences were diagnosed in the largest series of patients treated for an advanced-stage serous borderline ovarian tumour...
  42. ncbi request reprint [Prognosis and fertility after conservative treatment for ovarian tumors of limited malignity: review of 68 cases]
    S Camatte
    Service de chirurgie oncologique gynécologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Obstet Fertil 30:583-91. 2002
    ..The aim of this retrospective study was to evaluate the rate of recurrence and the reproductive outcome after surgical conservative treatment of low malignant ovarian tumors (LMOT)...
  43. doi request reprint [Is radical surgery (or parametrectomy) needed in all surgical procedure for early stage cervical cancer?]
    C Uzan
    Departement de Chirurgie, Institut Gustave Roussy, 39, 94805 Villejuif Cedex, France
    Gynecol Obstet Fertil 37:504-9. 2009
    ..This review reports studies exploring the safety of omitting parametrectomy in these low risk patients and the future possibilities to evaluate these new indications...
  44. ncbi request reprint [Initial or interval debulking surgery for advanced stage ovarian cancer: state-of-the-art. How to select patients?]
    P Morice
    Service de Chirurgie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Gynecol Obstet Fertil 33:55-63. 2005
    ..But criteria to select patients between initial and interval debulking surgery should be clearly defined. Those different points will be studied in this paper...
  45. doi request reprint [Adjuvant therapy and role of radiation therapy in advanced endometrial cancers]
    C Haie-Meder
    Service de curiethérapie, Institut Gustave Roussy, rue Camille Desmoulins, 94800 Villejuif, France
    Cancer Radiother 12:630-2. 2008
    ..Despite these advances, numerous questions remain on the best therapeutic sequence. Optimal chemotherapy regimens remain to be determined. On-going randomized trials will help to answer these questions...
  46. ncbi request reprint Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia
    C Even
    Department of Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France
    Eur J Cancer 50:2082-9. 2014
    ..Cisplatin (P) is a very active drug, but it is usually restricted to second-line therapies. Herein, we report the results of a cisplatin-based therapy: APE (actinomycin D, cisplatin, and etoposide)...
  47. ncbi request reprint [Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma]
    C Le Pechoux
    Institut Gustave Roussy, Villejuif, France
    Cancer Radiother 10:185-207. 2006
    ..This work is based on the methodology developed in the "Standards, Options and Recommendations" (SOR) project...
  48. ncbi request reprint [Endometrial surveillance of women on tamoxifen]
    C Lhomme
    Comité de gynécologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif, France
    Gynecol Obstet Fertil 31:647-56. 2003
    ..Besides, it is absolutely necessary to recommend them to take quickly medical advice in case of gynecologic symptoms...
  49. ncbi request reprint Ovarian metastasis on transposed ovary in patients treated for squamous cell carcinoma of the uterine cervix: report of two cases and surgical implications
    P Morice
    Department of Gynecologic Surgery, Radiotherapy, and Oncology, Institut Gustave Roussy, Villejuif, 94805, France
    Gynecol Oncol 83:605-7. 2001
    ..This procedure should not be performed in patients with bulky tumor and/or in patients with LVSI...
  50. ncbi request reprint Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature
    I Kloos
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 12:496-500. 2002
    ..The long latency period observed even in patients receiving only 5 years of treatment leads us also to consider a prolonged gynecologic follow-up of the patients...
  51. ncbi request reprint Chemoradiation therapy in pregnant patients treated for advanced-stage cervical carcinoma during the first trimester of pregnancy: report of two cases
    Y Benhaim
    Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex 94805, France
    Int J Gynecol Cancer 17:270-4. 2007
    ..Such management could be proposed in patients with a bulky cervical cancer diagnosed during the first trimester of the pregnancy. Management of the uterine evacuation depends on the local tumor spread...
  52. ncbi request reprint Retroperitoneal drainage after complete Para-aortic lymphadenectomy for gynecologic cancer: a randomized trial
    P Morice
    Department of Gynecologic Surgery, Imaging, Oncology and Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Obstet Gynecol 97:243-7. 2001
    ..To determine the relationship between retroperitoneal drainage after complete para-aortic lymphadenectomy for gynecologic cancer and subsequent development of lymphocysts...
  53. ncbi request reprint Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications
    P Morice
    Institut Gustave Roussy, 39 rue Camlle Desmoulins, Villejuif Cedex 94805, France
    Eur J Obstet Gynecol Reprod Biol 113:251-4. 2004
    ..5 years of follow-up after the end of adjuvant treatment. In order to ensure the exact spread of the disease. Lymphadenectomy should be performed in patients with ovarian cancer diagnosed at the time of prophylactic surgery...
  54. ncbi request reprint [Value of inhibin as a tumor marker in granulosa cell tumors. Apropos of 6 new cases treated at the Gustave-Roussy Institute]
    P Pautier
    Service de gynécologie médicale, Institut Gustave Roussy, Villejuif, France
    Bull Cancer 82:557-60. 1995
    ..In finding with other publications, inhibin can be used as a maker for reccurent disease, when patients are menopaused even when tumor does not produce steroids...
  55. ncbi request reprint Primary yolk sac tumor of the endometrium: a case report and review of the literature
    A Spatz
    Department of Pathology, Institut Gustave Roussy, Villejuif, 94805, France
    Gynecol Oncol 70:285-8. 1998
    ..On the basis of the small number of cases reported, such tumors appear to have clinical and pathological features similar to their ovarian counterparts...
  56. ncbi request reprint CT findings in two cases of port-site metastasis after laparoscopy for ovarian cancer
    J Viala
    Department of Radiology, Institut Gustave Roussy, Villejuif, France
    Eur J Gynaecol Oncol 23:293-4. 2002
    ..In both patients, CT scan revealed the presence of an heterogeneous nodular lesion inside the left oblique muscle. Histologic analysis confirmed the diagnosis of port-site recurrence...
  57. doi request reprint [New drugs and targeted therapeutic agents in ovarian cancer]
    T de La Motte Rouge
    Institut Gustave Roussy, Comité de gynécologie, Villejuif, France
    Bull Cancer 96:1215-24. 2009
    ..The goal remains to individualize and to tailor the drugs to the tumour biology, in order to provide personalized treatment to each patient...
  58. doi request reprint [Prognostic and predictive factors in epithelial ovarian cancer]
    P Boudou-Rouquette
    Comité de gynécologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 96:425-37. 2009
    ..none have modified today our clinical practices...
  59. ncbi request reprint Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study
    C Lhomme
    Medical Gynecologic Oncology Unit, Institut Gustave Roussy, Villejuif, France
    Leuk Lymphoma 42:1033-41. 2001
    ..In conclusion, leuprorelin administration is safe and effective in preventing vaginal bleeding. The sustained-release form and subcutaneous administration offer quality of life advantages...
  60. ncbi request reprint [What hysterectomy procedure should be carried out for cancer of the endometrium in stage I-II]
    Philippe Morice
    Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Bull Cancer 89:157-9. 2002
  61. ncbi request reprint Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary
    Sophie Camatte
    Gustave Roussy Institute, Villejuif, France
    BJOG 109:376-80. 2002
    ..To assess the fertility of patients treated conservatively for a Stage II or III borderline ovarian tumour...
  62. ncbi request reprint Results of conservative management of epithelial malignant and borderline ovarian tumours
    Philippe Morice
    Department of Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France
    Hum Reprod Update 9:185-92. 2003
    ..Removal of the preserved ovary should be carried out after completion of pregnancy(ies) in order to reduce the risk of ovarian tumour recurrence...
  63. ncbi request reprint Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
    Natacha Roger
    Service de Chirurgie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Ann Surg Oncol 15:333-8. 2008
    ....
  64. ncbi request reprint Exclusive radiotherapy for primary squamous cell carcinoma of the vagina
    Renaud de Crevoisier
    Department of Radiation Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Radiother Oncol 85:362-70. 2007
    ..To retrospectively analyze results of external beam therapy (EBT) with brachytherapy (BT) for primary vaginal squamous cell carcinoma (PVSCC)...
  65. ncbi request reprint Therapy Insight: fertility in women after cancer treatment
    Philippe Morice
    Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France
    Nat Clin Pract Endocrinol Metab 3:819-26. 2007
    ....
  66. doi request reprint Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies
    Sandrine Faivre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Eur J Cancer 44:674-82. 2008
    ..Promising antitumour activity was observed in patients with platinum-pretreated lung cancer...
  67. ncbi request reprint [New advances in screening and treatment of ovarian cancer]
    Philippe Morice
    Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 90:53-60. 2003
    ..Advances in chemotherapy and new drugs will be also studied in this paper...
  68. ncbi request reprint [Conservative management of malignant and borderline ovarian tumor]
    Philippe Morice
    Service de chirurgie oncologique gynécologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 89:1019-26. 2002
    ..A conservative management should not be performed in patients with tumor stage > IA and/or grade 3. Removal of preserved ovary should be performed after completion of pregnancy(ies) in order to reduce the risk of ovarian recurrence...
  69. doi request reprint Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy : correlation of radiologic findings with surgicopathologic results
    Etienne Vincens
    Department of Surgery, Gustave Roussy Institute and South Paris University, Villejuif, France
    Cancer 113:2158-65. 2008
    ..Very few studies have correlated MRI and histologic findings specifically in cervix cancer. This was the objective of the current study...
  70. ncbi request reprint Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes
    Catherine Uzan
    Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Ann Surg Oncol 11:658-64. 2004
    ..The aim was to study the prognosis for and survival of patients treated with combined therapy (including surgical resection) for nodal recurrences from epithelial ovarian cancer (EOC)...
  71. ncbi request reprint Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies
    Sophie Camatte
    J Am Coll Surg 195:332-8. 2002
    ..The aim of this study is to evaluate the rate and the clinical outcomes of lymph node involvement in patients treated for borderline ovarian tumor (BOT)...
  72. ncbi request reprint Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity
    Yann Delpech
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Ann Surg Oncol 14:3223-31. 2007
    ..The aim of this study was twofold: to evaluate the rate of histological PA+ after PCRT and to determine the survival of patients with PA+...
  73. ncbi request reprint [HIV and uterine cervical cancer]
    Patricia Pautier
    Oncolague médical, Comité de gynécologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 90:399-404. 2003
    ..Antiviral treatment and infectious prophylaxis have to be reinforced. A special care will be required for radiotherapy technical execution and clinical (digestive) and hematological follow-up through out the treatment...
  74. ncbi request reprint Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations
    Ludovic Lacroix
    Int J Cancer 118:1068-9. 2006
  75. ncbi request reprint Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
    ..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
  76. ncbi request reprint [Concomitant chemoradiation in patients with cervix cancer]
    Christine Haie-Meder
    Service de curiethérapie, Departement de Radiotherapie, Institut Gustave Roussy, rue Camille Desmoulins, 94800 Villejuif
    Bull Cancer 92:1032-8. 2005
    ..Future randomised trials should also aim to establish optimal chemotherapy regimens for combination with radiotherapy...
  77. ncbi request reprint Is systemic disease in the coelomic epithelium associated with BRCA1 germline mutations?
    Patricia Pautier
    J Natl Cancer Inst 96:488-9. 2004
  78. ncbi request reprint [Medical treatment of metastatic or recurrent cancer of the cervix]
    Thibault de La Motte Rouge
    Comité de gynécologie médicale, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex
    Bull Cancer 93:263-70. 2006
    ..However, the bad prognosis of this illness leads to keep on looking for better treatments. Targeted therapeutics and immunotherapy against human papilloma virus could bear significant progress for treatment of cervical cancer...
  79. ncbi request reprint Results of hysterectomy in patients with bulky residual disease at the end of chemoradiotherapy for stage IB2/II cervical carcinoma
    Elie Azria
    Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Ann Surg Oncol 12:332-7. 2005
    ..We assessed the clinical outcome after hysterectomy in patients with bulky residual disease after chemoradiotherapy for stage IB2/II cervical carcinoma...
  80. ncbi request reprint Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies
    Herve Ghesquieres
    Department of Medicine, Institut Gustave Roussy, Villejuif
    Invest New Drugs 24:413-21. 2006
    ..5 mg/m2/d topotecan on days 1-5. This study results suggest that alternative schedules of this combination are required...
  81. ncbi request reprint Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma
    Gil Dubernard
    Service de Chirurgie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Gynecol Oncol 97:136-41. 2005
    ..The aim of this study was to determine the rates and topography of pelvic and para-aortic nodal involvement in patients with stage III or IV primary peritoneal serous papillary carcinoma (PSPC)...
  82. ncbi request reprint Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer
    Philippe Morice
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    J Am Coll Surg 197:955-63. 2003
    ..Results of IDS (after three to four courses of induction chemotherapy) were compared with PDS followed by chemotherapy in patients treated for advanced stage ovarian cancer (stage IIIC or IV)...
  83. ncbi request reprint Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review
    Olivier Picone
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Gynecol Oncol 94:600-4. 2004
    ..To report a case of successful management of a FIGO stage III endometrioid carcinoma of the ovary diagnosed during pregnancy at 22 weeks of gestation and treated with initial chemotherapy while preserving the pregnancy...
  84. ncbi request reprint Neoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progression
    Yves Benhaim
    Eur J Obstet Gynecol Reprod Biol 136:267-8. 2008
  85. ncbi request reprint Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications
    Philippe Morice
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    J Am Coll Surg 197:198-205. 2003
    ..The purpose was to determine the factors influencing nodal involvement and topography of pelvic and paraaortic node involvement in ovarian carcinoma...
  86. ncbi request reprint Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases
    Sophie Camatte
    Department of Surgery, Institut Gustave Roussy, Service de Chirurgie, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Cancer 40:1842-9. 2004
    ....
  87. ncbi request reprint Malignant effusions and immunogenic tumour-derived exosomes
    Fabrice Andre
    Departments of Clinical Biology, Immunology Unit, Institut Gustave Roussy, Villejuif, France
    Lancet 360:295-305. 2002
    ..To assess the role of these exosomes in vivo, we examined malignant effusions for their presence. We also investigated whether these exosomes could induce production of tumour-specific T cells when pulsed with dendritic cells...
  88. ncbi request reprint [Sentinel lymph nodes in gynecologic cancers]
    David Atallah
    Departement de Chirurgie Oncologique, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 89:681-8. 2002
    ..An evaluation of the technique and the applicability in these cancers is mandatory in view of the prognostic value of the nodal involvement in these patients...
  89. ncbi request reprint [Intraperitoneal chemotherapy in first-line combination treatment for advanced ovarian cancer]
    Christophe Massard
    Institut Gustave Roussy, Departement de Medecine, 39, rue Camille Desmoulins, 94807 Villejuif Cedex
    Bull Cancer 94:398-404. 2007
    ....
  90. ncbi request reprint [Gynecological cancers and pregnancy: the point of view of the oncology gynecologist]
    Philippe Morice
    Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 89:765-71. 2002
    ..But such management needs to be determined in a multidisciplinary staff with oncologists, neonatologists, obstetricians but also the point of view of the patient...
  91. ncbi request reprint Re: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: a randomized clinical trial
    Philippe Morice
    J Natl Cancer Inst 97:1620-1; author reply 1621-3. 2005
  92. ncbi request reprint Necrotic cutaneous lesions induced by hypereosinophilic syndrome secondary to a T-cell lymphoma
    Selim Aractingi
    Unite de Dermatologie, Hopital Tenon, Paris, France
    J Am Acad Dermatol 46:S133-6. 2002
    ..Cutaneous lesions of HES are protean and probably reflect the differences between the lesional events induced in situ by activated eosinophils...
  93. ncbi request reprint Safety of simple cystectomy in patients with unilateral mucinous borderline tumors
    Laurent J Salomon
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Fertil Steril 85:1510.e1-4. 2006
    ..To report on ovarian carcinoma development after cystectomy for a borderline mucinous ovarian tumor...
  94. ncbi request reprint Peripheral neuropathy in association with an ovarian dysgerminoma
    Arben Ivanaj
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Oncol 89:168-70. 2003
    ..Peripheral neuropathy among women with ovarian dysgerminoma has not been so far reported in the literature...
  95. ncbi request reprint Endometrial disorders in patients with peritoneal serous papillary carcinoma
    Abdi Bafghi
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Obstet Gynecol Reprod Biol 134:101-4. 2007
    ..The purpose of this study was to evaluate the incidence rate of endometrial disease, particularly endometrial carcinoma, in patients with primary peritoneal serous papillary carcinoma (PSPC)...
  96. ncbi request reprint Growing teratoma syndrome after ovarian germ cell tumors
    Livia Zagamé
    Medical Oncologic Department, Pathologic Unit, Institut Gustave Roussy, Villejuif, France
    Obstet Gynecol 108:509-14. 2006
    ..To analyze a series of occurrences of growing teratoma syndrome after ovarian germ cell tumors...
  97. ncbi request reprint Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors
    Nelly Motté
    Int J Cancer 121:2113-5. 2007